Thymosin Alpha-1 reconstitution calculator
Type in a vial size, the diluent volume you added, and a dose figure — the calculator below converts those three numbers into a concentration, a draw volume, and a syringe reading. It performs the same arithmetic as our tirzepatide and sermorelin calculators. What it cannot do, for Thymosin Alpha-1 specifically, is confirm your vial matches an FDA-approved U.S. product, since none exists — even though a real approved version is sold in dozens of other countries. Read why below before you use it.
Approved in 35+ countries as Zadaxin — never approved in the U.S.
Thymosin Alpha-1's synthetic pharmaceutical form, thymalfasin, is genuinely approved and marketed in more than 35 countries as Zadaxin, for hepatitis B/C and as an immune adjuvant, per a 2020 peer-reviewed review. That is a real international approval record, and it makes this compound's regulatory picture different from almost every other molecule on this calculator hub. What it does not have is FDA marketing approval in the United States: checked live against two independent federal databases, openFDA's Drugs@FDA returns zero matches for "thymalfasin" or "Zadaxin" — no New Drug Application of any kind is on file — and DailyMed's structured-product-label search independently returns zero results. Any FDA orphan-drug designation this compound has carried at points is a separate, narrower status than marketing approval, and this page does not conflate the two.
Real human trial data exists behind its international approval: a meta-analysis of 7 randomized controlled trials (535 patients) found thymosin alpha-1 combined with interferon significantly outperformed interferon alone for chronic hepatitis B. A separate 361-patient randomized trial for severe sepsis found a real but borderline-significant mortality reduction. Neither trial supports any specific dose for the uses this compound is sold for outside a clinical, prescriber-directed setting.
What the tool below actually does is narrower than that context might suggest: it takes the vial size, diluent volume, and dose you type in and returns the concentration and draw volume that arithmetic implies — nothing more. It cannot confirm that a vial matches an internationally-approved Zadaxin product, or that a dose matches either of the two trial protocols described above.
Sources: Dominari A et al., World J Virol 2020 (PMID 33362999), openFDA's Drugs@FDA database, DailyMed's structured-product-label listings, and FDA's current 503A Bulks List and companion significant-safety-risk page, all independently checked August 2026. View the DailyMed search.
Thymosin Alpha-1 reconstitution
Fill in all three fields to see exactly where the plunger lands.
Where to go next
- Read the full sourcing trail — the international approval record, the U.S. regulatory gap, and what the hepatitis B and sepsis trials actually found — on our Thymosin Alpha-1 evidence review.
- See a different immunomodulatory peptide with a much thinner formal trial base and no approved product in any country, on our VIP evidence review.
- Compare against the compounds this calculator supports that have a currently-approved U.S. reference product, on the calculator hub.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.